Mutations in ASXL1, RUNX1, and STAG2 were significantly more common in patients with MDS and increased blasts (MDS-IB) than in those with MDS-LB in the 2022 WHO (p < 0.05; Table 2). This evidence concerns the gene RUNX1 and myelodysplastic syndrome.